Outcome of inflammatory bowel disease patients treated with TNF-α inhibitors: two-year follow-up

Biological medications, particularly TNF-α inhibitors, are used increasingly for active inflammatory bowel disease (IBD). Even though they are superior to many older medications in achieving remission and mucosal healing, primary nonresponse and loss of response remain significant problems, and a remarkable proportion of patients still need surgery at some point.To study the outcome of IBD patients treated with TNF-α inhibitors, either...